Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Exenatide

Stage Phase 3Stale

Sponsor AstraZeneca

Route oral and injection

Class GLP-1 RA

Mechanism Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients

Sources

registry, as of 2015-04-07Stale

https://clinicaltrials.gov/study/NCT00375492

Effect on Weight Loss of Exenatide Versus Placebo. Overall status COMPLETED. Phases PHASE3. Lead sponsor AstraZeneca. Enrollment 196. Conditions Type 2 Diabetes Mellitus. This trial is designed to compare the effects of twice-daily exenatide and twice-daily placebo on weight loss. This trial will evaluate overweight and obese subjects with type 2 diabetes who have inadequate glycemic control with metformin, sulfonylurea, or metformin plus a sulfon nausea Group A (Exenatide) 43 diarrhea Group A (Exenatide) 18 vomiting Group A (Exenatide) 21 nausea Group B (Placebo) 19 diarrhea Group B (Placebo) 21 vomiting Group B (Placebo) 9

ClinicalTrials.gov NCT00375492 protocol and results modules

registry, as of 2021-04-09Stale

https://clinicaltrials.gov/study/NCT03671733

Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients. Overall status UNKNOWN. Phases PHASE3. Lead sponsor Xiangya Hospital of Central South University. Enrollment 150. Conditions Obesity. This studay evaluates the effect of the glucagon-like peptide-1 (GLP-1) receptor agonist,including Liraglutide,Exenatide and Exenatide Microspheres for Injection,in the treatment of subjects who are overweight or obese.

ClinicalTrials.gov NCT03671733 protocol and results modules

registry, as of 2019-06-04Stale

https://clinicaltrials.gov/study/NCT00856609

The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects. Overall status COMPLETED. Phases PHASE3. Lead sponsor National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Enrollment 150. Conditions Weight Loss; Obesity. Exenatide is an incretin-like drug that has been approved for treatment of type 2 diabetes; it improves glycemia by increasing insulin and decreasing glucagon secretion by pancreatic islet cells and delaying gastric emptying. This randomized, placebo-controlled study is to evalua deaths Exenatide 0 nausea Exenatide 24 diarrhea Exenatide 16 vomiting Exenatide 11 deaths Placebo 0 nausea Placebo 19 diarrhea Placebo 16 vomiting Placebo 8

ClinicalTrials.gov NCT00856609 protocol and results modules

registry, as of 2021-01-29Stale

https://clinicaltrials.gov/study/NCT02635386

EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS). Overall status COMPLETED. Phases PHASE3. Lead sponsor Woman's. Enrollment 119. Conditions Polycystic Ovary Syndrome; Obesity. This is a randomized, single-blind, parallel 5 treatment group 24-week trial designed to directly compare the therapeutic effects of exenatide once weekly (EQW), dapagliflozin (DAPA), EQW plus DAPA, combined DAPA/metformin extended release (XR) and the weight loss medication, phe Change in Percent Body Weight Exenatide Once Weekly (EQW ) 3.8 percentage change in body weight Change from baseline (time 0) to study end (24 weeks) Change in Percent Body Weight Dapagliflozin (DAPA) 1.5 percentage change in body weight Change from baseline (time 0) to study end (24 weeks) Change in Percent Body Weight EQW Plus DAPA 6.9 percentage change in body weight Change from baseli

ClinicalTrials.gov NCT02635386 protocol and results modules

registry, as of 2026-01-05Stale

https://clinicaltrials.gov/study/NCT04520490

Brain Activation and Satiety in Children 2. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Seattle Children's Hospital. Enrollment 63. Conditions Childhood Obesity. Childhood obesity and related long-term effects are serious public health problems, but not all children with obesity do well in treatment. This study will test a new combination of family-based behavioral treatment (FBT) with a drug intervention using a glucagon-like peptide-1 r

ClinicalTrials.gov NCT04520490 protocol and results modules

registry, as of 2015-06-24Stale

https://clinicaltrials.gov/study/NCT01794429

Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue. Overall status COMPLETED. Phases PHASE3. Lead sponsor Bjorn H. Ebdrup. Enrollment 45. Conditions Obesity; Metabolic Syndrome X; Drug-induced Obesity; Schizophrenia. To examine if 3 months of treatment with a GLP-1 (glucagon-like-peptide-1) analogue can induce weight loss in obese, non-diabetic patients with a diagnosis within the schizophrenic spectrum. The investigators will also examine possible associations between GLP-1 treatment and pe

ClinicalTrials.gov NCT01794429 protocol and results modules

registry, as of 2026-05-22Stale

https://clinicaltrials.gov/study/NCT02860923

Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy. Overall status COMPLETED. Phases PHASE3. Lead sponsor University Hospital, Bordeaux. Enrollment 42. Conditions Craniopharyngiomas; Hypothalamic Obesity. This hypothalamic obesity is associated with serious metabolic and psychosocial consequences. The purpose of the study is to compare the change of body weight after 6 months treatment with a lifestyle intervention + exenatide compare to the one after the same lifestyle intervent

ClinicalTrials.gov NCT02860923 protocol and results modules

registry, as of 2022-05-05Stale

https://clinicaltrials.gov/study/NCT02664441

Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Seattle Children's Hospital. Enrollment 42. Conditions Hypothalamic Obesity. The proposed multicenter study will test the effect of glucagon-like peptide (GLP)-1 agonist exenatide once weekly extended-release (ExQW, Bydureon®) on clinical outcomes and metabolic parameters in a double-blind, placebo-controlled 36 week randomized trial with an 18 week open Percent Change of Body Mass Index (BMI) as Calculated by the Formula: Body Weight in kg Divided by Height in Meters². Exenatide Once Weekly Extended-release 1.7 percent change from baseline From baseline to 36 weeks Percent Change of Body Mass Index (BMI) as Calculated by the Formula: Body Weight in kg Divided by Height in Meters². Matching Placebo 3.5 percent change from ba

ClinicalTrials.gov NCT02664441 protocol and results modules

registry, as of 2009-03-31Stale

https://clinicaltrials.gov/study/NCT00872378

The Effects of Exenatide After Gastric Restriction. Overall status UNKNOWN. Phases PHASE2,PHASE3. Lead sponsor Advanced Specialty Care. Enrollment 28. Conditions Morbid Obesity. The purpose of this study is to describe change in body weight in non-diabetic morbidly obese patients after laparoscopic adjustable gastric banding (LAGB) with twice daily exenatide or placebo injections.

ClinicalTrials.gov NCT00872378 protocol and results modules

registry, as of 2020-03-31Stale

https://clinicaltrials.gov/study/NCT03419624

The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients. Overall status TERMINATED. Phases PHASE3. Lead sponsor Universitätsklinikum Hamburg-Eppendorf. Enrollment 13. Conditions Obesity; Diabetes Mellitus, Type 2. This is a 28-week, multi-center, randomized, double-blind, placebo-controlled trial to study a potential synergistic effect of Dapagliflozin plus Exenatide once-weekly in combination with high-dose intensive insulin therapy compared to Placebo in obese insulin-resistant patients

ClinicalTrials.gov NCT03419624 protocol and results modules

registry, as of 2015-04-07Stale

https://clinicaltrials.gov/study/NCT00500370

A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients. Overall status COMPLETED. Phases PHASE2. Lead sponsor AstraZeneca. Enrollment 163. Conditions Obesity. This is a multicenter study designed to compare the effect of exenatide plus a lifestyle modification plan versus placebo plus a lifestyle modification plan on weight loss in non-diabetic, obese subjects. Percentage of Patients Experiencing >=5% Weight Loss Group A (Exenatide) 31.5 Percentage of Patients Experiencing >=5% Weight Loss Group B (Placebo) 16.5 nausea Group A (Exenatide) 18 diarrhea Group A (Exenatide) 10 vomiting Group A (Exenatide) 6 nausea Group B (Placebo) 3 diarrhea Group B (Placebo) 2 vomiting Group B (Placebo) 1

ClinicalTrials.gov NCT00500370 protocol and results modules

registry, as of 2021-01-28Stale

https://clinicaltrials.gov/study/NCT02975297

Exenatide Once Weekly for Smoking Cessation. Overall status COMPLETED. Phases PHASE1,PHASE2. Lead sponsor The University of Texas Health Science Center, Houston. Enrollment 84. Conditions Smoking Cessation. The purpose of this study is to identify a potential new treatment for smoking cessation. deaths Exenatide Plus NRT Plus Counseling 0 deaths Placebo Plus NRT Plus Counseling 0

ClinicalTrials.gov NCT02975297 protocol and results modules

registry, as of 2007-07-11Stale

https://clinicaltrials.gov/study/NCT00344851

Exenatide and Metformin Therapy in Overweight Women With PCOS. Overall status COMPLETED. Phases PHASE2. Lead sponsor Metabolic Center of Louisiana Research Foundation. Enrollment 60. Conditions Polycystic Ovary Syndrome. Current research has shown that the use of diabetes management practices aimed at reducing insulin resistance and hyperinsulinemia (such as weight reduction and the administration of oral antidiabetic drugs) in women with PCOS can not only improve glucose and lipid metabolism but

ClinicalTrials.gov NCT00344851 protocol and results modules

registry, as of 2016-11-17Stale

https://clinicaltrials.gov/study/NCT02313220

Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight. Overall status COMPLETED. Phases PHASE2. Lead sponsor Uppsala University. Enrollment 50. Conditions Obesity. Obesity is a medical condition which increases the risk of other diseases, such as type 2 diabetes and cardiovascular disease. Obesity-related risk factors for the development of other metabolic diseases include unstable glucose levels and high blood pressure. Dapagliflozin and e

ClinicalTrials.gov NCT02313220 protocol and results modules

registry, as of 2022-05-18Stale

https://clinicaltrials.gov/study/NCT02794402

Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMI. Overall status COMPLETED. Phases PHASE2. Lead sponsor Uppsala University. Enrollment 44. Conditions Obesity. Combat-JUDO (Combating Juvenile Diabetes and Obesity through normalization of beta-cell function) is part of a collaborative project funded by the Seventh Framework Programme of the European Commission aiming to develop innovative therapeutic strategies by increasing pharmacology

ClinicalTrials.gov NCT02794402 protocol and results modules

Studies

Effect on Weight Loss of Exenatide Versus Placebo

Registry NCT00375492

Phase Phase 3

Status Completed

Enrollment 196

Group A

Regimen twice daily

Comparator placebo

Population Type 2 Diabetes Mellitus

participants with nausea, 43 participantsStale

participants with diarrhea, 18 participantsStale

participants with vomiting, 21 participantsStale

Group B

Regimen twice daily

Population Type 2 Diabetes Mellitus

participants with nausea, 19 participantsStale

participants with diarrhea, 21 participantsStale

participants with vomiting, 9 participantsStale

Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients

Registry NCT03671733

Phase Phase 3

Enrollment 150

Start 2018-09-01

Primary completion 2022-09-01

Study completion 2022-09-01

Liraglutide

Regimen once daily

Weeks 4

Population Obesity

Exenatide

Regimen twice daily

Weeks 4

Population Obesity

Exenatide Microspheres for Injection

Regimen once weekly

Weeks 4

Population Obesity

The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects

Registry NCT00856609

Phase Phase 3

Status Completed

Enrollment 150

Start 2009-03-03

Primary completion 2016-09-19

Study completion 2016-09-19

Exenatide

Regimen twice daily

Weeks 5

Comparator placebo

Population Weight Loss; Obesity

deaths

participants with nausea, 24 participantsStale

participants with diarrhea, 16 participantsStale

participants with vomiting, 11 participantsStale

Placebo

Regimen twice daily

Weeks 5

Population Weight Loss; Obesity

deaths

participants with nausea, 19 participantsStale

participants with diarrhea, 16 participantsStale

participants with vomiting, 8 participantsStale

EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)

Registry NCT02635386

Phase Phase 3

Status Completed

Enrollment 119

Start 2016-03-22

Primary completion 2020-07-22

Study completion 2020-10-09

Exenatide once weekly (EQW )

Regimen once weekly

Weeks 4

Population Polycystic Ovary Syndrome; Obesity

percent change in body weight, 3.8 %, week 24Stale

deaths

Dapagliflozin (DAPA)

Regimen once daily

Weeks 4

Population Polycystic Ovary Syndrome; Obesity

percent change in body weight, 1.5 %, week 24Stale

deaths

EQW plus DAPA

Regimen once daily

Weeks 4

Population Polycystic Ovary Syndrome; Obesity

percent change in body weight, 6.9 %, week 24Stale

deaths

Dapagliflozin plus Glucophage (MET ER)

Regimen daily

Weeks 4

Population Polycystic Ovary Syndrome; Obesity

percent change in body weight, 1.7 %, week 24Stale

deaths

Phentermine /Topiramate (PHEN/ TPM) ER

Regimen once daily

Weeks 4

Population Polycystic Ovary Syndrome; Obesity

percent change in body weight, 8.1 %, week 24Stale

deaths

BASIC2

Registry NCT04520490

Phase Phase 3

Status Active, not recruiting

Enrollment 63

Start 2021-01-28

Primary completion 2025-08-21

Study completion 2026-02-12

Catalyst Primary completion. 2025-08-21. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Exenatide once weekly extended-release

Regimen once weekly

Weeks 24

Comparator placebo

Population Childhood Obesity

Matching placebo

Regimen weekly

Weeks 24

Population Childhood Obesity

TAO

Registry NCT01794429

Phase Phase 3

Status Completed

Enrollment 45

Placebo

Regimen once weekly

Population Obesity; Metabolic Syndrome X; Drug-induced Obesity; Schizophrenia

exenatide

Regimen once weekly

Comparator placebo

Population Obesity; Metabolic Syndrome X; Drug-induced Obesity; Schizophrenia

CRANIOEXE

Registry NCT02860923

EudraCT 2013-004755-21

Phase Phase 3

Status Completed

Enrollment 42

Start 2017-01-11

Primary completion 2018-06-30

Study completion 2018-09-30

Exenatide

Comparator placebo

Population Craniopharyngiomas; Hypothalamic Obesity

Placebo

Population Craniopharyngiomas; Hypothalamic Obesity

ECHO

Registry NCT02664441

Phase Phase 3

Status Completed

Enrollment 42

Primary completion 2020-03-16

Study completion 2020-07-31

Exenatide once weekly extended-release

Regimen once weekly

Weeks 36

Comparator placebo

Population Hypothalamic Obesity

percent change in body weight, 1.7 %, week 36Stale

deaths

participants with nausea, 6 participantsStale

participants with diarrhea, 7 participantsStale

participants with vomiting, 4 participantsStale

Matching placebo

Regimen once weekly

Weeks 36

Population Hypothalamic Obesity

percent change in body weight, 3.5 %, week 36Stale

deaths

participants with nausea, 3 participantsStale

participants with diarrhea, 3 participantsStale

participants with vomiting, 4 participantsStale

AGREE

Registry NCT00872378

Phase Phase 2/3

Enrollment 28

Exenatide

Regimen twice daily

Weeks 4

Comparator placebo

Population Morbid Obesity

Placebo

Regimen twice daily

Weeks 4

Population Morbid Obesity

The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients

Registry NCT03419624

Phase Phase 3

Status Terminated

Enrollment 13

Start 2018-02-19

Primary completion 2019-04-01

Study completion 2019-08-05

Dapagliflozin plus Exenatide

Regimen once weekly

Comparator placebo

Population Obesity; Diabetes Mellitus, Type 2

Placebo plus Placebo

Regimen once weekly

Population Obesity; Diabetes Mellitus, Type 2

Placebo plus Exenatide

Regimen once daily

Population Obesity; Diabetes Mellitus, Type 2

A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients

Registry NCT00500370

Phase Phase 2

Status Completed

Enrollment 163

Group A

Weeks 24

Comparator placebo

Population Obesity

participants with at least 5 percent body weight loss, 31.5 %, week 24Stale

participants with nausea, 18 participantsStale

participants with diarrhea, 10 participantsStale

participants with vomiting, 6 participantsStale

Group B

Weeks 24

Population Obesity

participants with at least 5 percent body weight loss, 16.5 %, week 24Stale

participants with nausea, 3 participantsStale

participants with diarrhea, 2 participantsStale

participants with vomiting, 1 participantsStale

Exenatide Once Weekly for Smoking Cessation

Registry NCT02975297

Phase Phase 1/2

Status Completed

Enrollment 84

Primary completion 2020-01-03

Study completion 2020-01-03

Exenatide plus NRT plus counseling

Regimen once weekly

Weeks 6

Comparator placebo

Population Smoking Cessation

deaths

Placebo plus NRT plus counseling

Regimen once weekly

Weeks 6

Population Smoking Cessation

deaths

Exenatide and Metformin Therapy in Overweight Women With PCOS

Registry NCT00344851

Phase Phase 2

Status Completed

Enrollment 60

Registry arm not named

Population Polycystic Ovary Syndrome

Dapalost

Registry NCT02313220

EudraCT 2014-003432-39

Phase Phase 2

Status Completed

Enrollment 50

Dapagliflozin and exenatide

Regimen once weekly

Weeks 24

Comparator placebo

Population Obesity

Placebo

Regimen once weekly

Weeks 24

Population Obesity

Combat-JUDO

Registry NCT02794402

Phase Phase 2

Status Completed

Enrollment 44

Bydureon

Regimen once weekly

Weeks 24

Comparator placebo

Population Obesity

Placebo

Regimen once weekly

Weeks 24

Population Obesity